CLC number: R446
On-line Access: 2019-06-06
Received: 2019-01-29
Revision Accepted: 2019-04-14
Crosschecked: 2019-05-23
Cited: 0
Clicked: 3045
Ai-Bin Zhang, Yi-Fan Peng, Jun-Jun Jia, Yu Nie, Shi-Yu Zhang, Hai-Yang Xie, Lin Zhou, Shu-Sen Zheng. Exosome-derived galectin-9 may be a novel predictor of rejection and prognosis after liver transplantation[J]. Journal of Zhejiang University Science B,in press.Frontiers of Information Technology & Electronic Engineering,in press.https://doi.org/10.1631/jzus.B1900051 @article{title="Exosome-derived galectin-9 may be a novel predictor of rejection and prognosis after liver transplantation", %0 Journal Article TY - JOUR
外泌体来源的半乳糖凝集素-9预测肝移植术后排斥发生及预后创新点:本研究发现外泌体及内含物半乳糖凝集素-9(galectin-9)在肝移植术后排斥及预后预测中发挥重要作用. 方法:分别从急性排斥和肝功能稳定患者提取外泌体,进行分离、鉴定并检测其内含蛋白.候选蛋白通过在73个急性排斥病人和63个肝功能稳定病人切除肝的组织芯片中进行验证.最后将蛋白表达量和临床参数纳入Kaplan-Meier生存率和Cox回归分析. 结论:外泌体来源的galectin-9可作为预测肝移植术后排斥发生及预后的生物学指标. 关键词组: Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article
Reference[1]Ashokkumar C, Soltys K, Mazariegos G, et al., 2017. Predicting cellular rejection with a cell-based assay: preclinical evaluation in children. Transplantation, 101(1):131-140. [2]Boix F, Millan O, san Segundo D, et al., 2016. High expression of CD38, CD69, CD95 and CD154 biomarkers in cultured peripheral T lymphocytes correlates with an increased risk of acute rejection in liver allograft recipients. Immunobiology, 221(5):595-603. [3]Chagan-Yasutan H, Shiratori B, Siddiqi UR, et al., 2010. The increase of plasma galectin-9 in a patient with insulin allergy: a case report. Clin Mol Allergy, 8:12. [4]Chen DJ, Peng WH, Jiang H, et al., 2017. Noninvasive detection of acute renal allograft rejection by measurement of soluble Tim-3 in urine. Mol Med Rep, 16(1):915-921. [5]Dardalhon V, Anderson AC, Karman J, et al., 2010. Tim-3/ galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. J Immunol, 185(3):1383-1392. [6]Demetris AJ, Bellamy C, Hübscher SG, et al., 2016. 2016 comprehensive update of the Banff Working Group on Liver Allograft Pathology: introduction of antibody-mediated rejection. Am J Transplant, 16(10):2816-2835. [7]Dieudé M, Bell C, Turgeon J, et al., 2015. The 20S proteasome core, active within apoptotic exosome-like vesicles, induces autoantibody production and accelerates rejection. Sci Transl Med, 7(318):318ra200. [8]Gupta S, Thornley TB, Gao WD, et al., 2012. Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs. J Clin Invest, 122(7):2395-2404. [9]Huang HT, Lu YF, Zhou T, et al., 2018. Innate immune cells in immune tolerance after liver transplantation. Front Immunol, 9:2401. [10]Kerr N, García-Contreras M, Abbassi S, et al., 2018. Inflammasome proteins in serum and serum-derived extracellular vesicles as biomarkers of stroke. Front Mol Neurosci, 11:309. [11]Kim N, Yoon YI, Yoo HJ, et al., 2016. Combined detection of serum IL-10, IL-17, and CXCL10 predicts acute rejection following adult liver transplantation. Mol Cells, 39(8):639-644. [12]https://doi.org/10.14348/molcells.2016.0130 [13]Kurose Y, Wada J, Kanzaki M, et al., 2013. Serum galectin-9 levels are elevated in the patients with type 2 diabetes and chronic kidney disease. BMC Nephrol, 14:23. [14]Lazar E, Benedek T, Korodi S, et al., 2018. Stem cell-derived exosomes—an emerging tool for myocardial regeneration. World J Stem Cells, 10(8):106-115. [15]Lee EC, Kim SH, Park SJ, 2017. Outcomes after liver transplantation in accordance with ABO compatibility: a systematic review and meta-analysis. World J Gastroenterol, 23(35):6516-6533. [16]Li YM, Shi YY, Li Y, et al., 2018. Soluble Tim-3 and Gal-9 are associated with renal allograft dysfunction in kidney transplant recipients: a cross-sectional study. Int Immunopharmacol, 55:330-335. [17]Lim JH, Lee CH, Kim KY, et al., 2018. Novel urinary exosomal biomarkers of acute T cell-mediated rejection in kidney transplant recipients: a cross-sectional study. PLoS ONE, 13(9):e0204204. [18]Meszaros M, Ursic-Bedoya J, Faure S, et al., 2019. Immuno-suppression minimization trials in liver transplantation: can we predict humoral response to assess eligibility? Hepatology, 69(5):2302-2303. [19]Mousavi S, Moallem R, Hassanian SM, et al., 2019. Tumor-derived exosomes: potential biomarkers and therapeutic target in the treatment of colorectal cancer. J Cell Physiol, 234(8):12422-12432. [20]Naderi-Meshkin H, Lai X, Amirkhah R, et al., 2019. Exosomal lncRNAs and cancer: connecting the missing links. Bioinformatics, 35(2):352-360. [21]Naka EL, Ponciano VC, Cenedeze MA, et al., 2009. Detection of the Tim-3 ligand, galectin-9, inside the allograft during a rejection episode. Int Immunopharmacol, 9(6):658-662. [22]Pike R, Thomas N, Workman S, et al., 2016. PD1-expressing T cell subsets modify the rejection risk in renal transplant patients. Front Immunol, 7:126. [23]Qiao XW, Jiang K, Nie J, et al., 2014. Increased expression of Tim-3 and its ligand galectin-9 in rat allografts during acute rejection episodes. Biochem Biophys Res Commun, 445(3):542-548. [24]Raschzok N, Reutzel-Selke A, Schmuck RB, et al., 2015. CD44 and CXCL9 serum protein levels predict the risk of clinically significant allograft rejection after liver transplantation. Liver Transpl, 21(9):1195-1207. [25]Saitoh H, Ashino Y, Chagan-Yasutan H, et al., 2012. Rapid decrease of plasma galectin-9 levels in patients with acute HIV infection after therapy. Tohoku J Exp Med, 228(2):157-161. [26]Sakuishi K, Jayaraman P, Behar SM, et al., 2011. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol, 32(8):345-349. [27]Schlegel A, Linecker M, Kron P, et al., 2017. Risk assessment in high- and low-meld liver transplantation. Am J Transplant, 17(4):1050-1063. [28]Shen T, Lin BY, Jia JJ, et al., 2014. A modified protocol with rituximab and intravenous immunoglobulin in emergent ABO-incompatible liver transplantation for acute liver failure. Hepatobiliary Pancreat Dis Int, 13(4):395-401. [29]Sood S, Haifer C, Yu LJ, et al., 2017. A novel immune function biomarker identifies patients at risk of clinical events early following liver transplantation. Liver Transpl, 23(4):487-497. [30]Su EW, Bi SG, Kane LP, 2011. Galectin-9 regulates T helper cell function independently of Tim-3. Glycobiology, 21(10):1258-1265. [31]Tang ZH, Liang SW, Potter J, et al., 2013. Tim-3/galectin-9 regulate the homeostasis of hepatic NKT cells in a murine model of nonalcoholic fatty liver disease. J Immunol, 190(4):1788-1796. [32]Vallabhajosyula P, Korutla L, Habertheuer A, et al., 2017. Tissue-specific exosome biomarkers for noninvasively monitoring immunologic rejection of transplanted tissue. J Clin Invest, 127(4):1375-1391. [33]van den Hoogen LL, van Roon JAG, Mertens JS, et al., 2018. Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis, 77(12):1810-1814. [34]Vitalone MJ, Wei L, Fujiki M, et al., 2016. Liver microRNA profile of induced allograft tolerance. Transplantation, 100(4):781-790. [35]Wang Y, Zhang M, Liu ZW, et al., 2014. The ratio of circulating regulatory T cells (Tregs)/Th17 cells is associated with acute allograft rejection in liver transplantation. PLoS ONE, 9(11):e112135. [36]Zhou YX, Yang XJ, Zhang H, et al., 2015. The roles of T helper type 17/regulatory T cells in acute rejection after liver transplantation in rats. Transplantation, 99(6):1126-1131. Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou
310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn Copyright © 2000 - 2024 Journal of Zhejiang University-SCIENCE |
Open peer comments: Debate/Discuss/Question/Opinion
<1>